Blair William & Co. IL Has $152.87 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Blair William & Co. IL increased its holdings of DexCom, Inc. by 0.3%, acquiring an additional 5,916 shares, bringing their total to 2,238,563 shares valued at $152.9 million.
• Several other institutional investors have also increased their stakes in DexCom, with 97.75% of the company's stock now owned by institutional investors.
• DexCom reported a quarterly earnings per share (EPS) of $0.48, beating estimates and showing a 15.2% year-over-year revenue increase.

Blair William & Co. IL increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,238,563 shares of the medical device company's stock after acquiring an additional 5,916 shares during the quarter. Blair William & Co. IL owned approximately 0.57% of DexCom worth $152,871,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DXCM. Golden State Wealth Management LLC lifted its holdings in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Optiver Holding B.V. bought a new stake in DexCom in the fourth quarter valued at $33,000. Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter valued at $38,000. Alpine Bank Wealth Management acquired a new stake in shares of DexCom in the 1st quarter worth about $40,000. Finally, Private Trust Co. NA increased its holdings in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. This represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,656 shares of company stock worth $2,412,191. Corporate insiders own 0.32% of the company's stock.

DexCom Stock Down 1.1%

Shares of DXCM stock traded down $0.80 on Tuesday, reaching $75.45. 1,551,437 shares of the company's stock traded hands, compared to its average volume of 3,887,930. The business's 50 day moving average price is $84.40 and its two-hundred day moving average price is $80.54. The company has a market capitalization of $29.59 billion, a P/E ratio of 52.32, a price-to-earnings-growth ratio of 1.66 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The firm's quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on DXCM shares. Oppenheimer raised their price target on shares of DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Robert W. Baird lowered their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. William Blair raised DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Mizuho increased their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Finally, Barclays raised their price target on DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.